Micro Interventional Devices, Inc.

Micro Interventional Devices, Inc. focuses on developing and commercializing advanced catheter-based technologies designed to treat structural heart diseases, enhancing patient care through innovative solutions. Micro Interventional Devices, Inc. is a company that specializes in catheter-based technologies for treating structural heart disease.

The company is headquartered in Newton, US. The CEO team comprises Christopher Thatcher, Michael Whitman, and Thomas Osypka. In March 2019, the company raised USD 20 mn in Series D funding led by Oscor, Inc. , with participation from Ben Franklin Technology Partners, Life Sciences Greenhouse of Central Pennsylvania, and Originate Ventures.

This funding supports their growth initiatives in the medical device sector. Micro Interventional Devices (MID) specializes in the design, manufacture, and commercialization of innovative catheter-based technologies aimed at treating structural heart disease. Their primary product, the MIA-T Percutaneous Tricuspid Annuloplasty System, is engineered for the treatment of tricuspid regurgitation, allowing for minimally invasive repair of the tricuspid valve through a percutaneous approach. This technology provides significant benefits to patients by reducing morbidity and recovery time, catering to healthcare institutions and interventional cardiologists, especially in North America and Europe.

The revenue model for Micro Interventional Devices is primarily based on direct sales of their medical device solutions to hospitals and healthcare providers involved in cardiovascular care. Transactions typically occur through a B2B structure, where medical institutions purchase the MIA-T System among other products for their cardiac care programs. Pricing reflects the specialized nature of the technology and its clinical benefits, fostering partnerships that improve patient outcomes. Training and support services accompany MID’s products, although specifics on pricing or transaction structures remain proprietary.

In March 2019, Micro Interventional Devices, Inc. raised USD 20 mn in Series D funding, which will be utilized to develop and launch new products aimed at enhancing treatment options in structural heart disease. The company plans to expand its market presence in Europe and Asia by 2021, aiming to reach healthcare providers seeking advanced solutions in interventional cardiology. This funding will facilitate the development of additional catheter-based technologies and support their market expansion strategy.